References
Schweitzer F, Laurent S, Cortese I et al (2023) Progressive multifocal leukoencephalopathy: pathogenesis, diagnostic tools, and potential biomarkers of response to therapy. Neurology 101:700–713. https://doi.org/10.1212/WNL.0000000000207622
Cortese I, Muranski P, Enose-Akahata Y et al (2019) Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med 380:1597–1605. https://doi.org/10.1056/NEJMoa1815039
Roos-Weil D, Weiss N, Guihot A et al (2021) Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: a new gold standard? J Neurol 268:2458–2465. https://doi.org/10.1007/s00415-021-10414-y
Boumaza X, Bonneau B, Roos‐Weil D, et al (2022) Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors. Ann Neurol 15: 10. Doi: https://doi.org/10.1002/ana.26512
Barber DL, Wherry EJ, Masopust D et al (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682–687. https://doi.org/10.1038/nature04444
Girón-González JA, Alvarez-Mon M, Menéndez-Caro JL et al (1994) T lymphocytes from alcoholic cirrhotic patients show normal interleukin-2 production but a defective proliferative response to polyclonal mitogens. Am J Gastroenterol 89:767–773
Gomez F, Ruiz P, Schreiber AD (1994) Impaired Function of Macrophage Fcγ Receptors and Bacterial Infection in Alcoholic Cirrhosis. N Engl J Med 331:1122–1128. https://doi.org/10.1056/NEJM199410273311704
Laso FJ, Madruga JI, Giron JA et al (1997) Decreased natural killer cytotoxic activity in chronic alcoholism is associated with alcohol liver disease but not active ethanol consumption. Hepatology 25:1096–1100. https://doi.org/10.1002/hep.510250508
Acket B, Guillaume M, Tardy J et al (2010) Progressive multifocal leukoencephalopathy in a patient with alcoholic cirrhosis. Gastroenterol Clin Biol 34:336–338. https://doi.org/10.1016/j.gcb.2010.02.002
Gheuens S, Pierone G, Peeters P, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry 81:247–254. https://doi.org/10.1136/jnnp.2009.187666
Berger JR, Aksamit AJ, Clifford DB et al (2013) PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 80:1430–1438. https://doi.org/10.1212/WNL.0b013e31828c2fa1
Funding
This study did not receive any funding.
Author information
Authors and Affiliations
Contributions
LJ wrote the first draft of the manuscript. NS and LJ designed the figures. All authors participated in the diagnosis and therapy deliberation. All authors reviewed and approved the final manuscript. The patients provided informed consent for the publication of this report. Data was collected and managed in accordance with the CARE statement checklist (https://www.care-statement.org/checklist).
Corresponding author
Ethics declarations
Conflicts of interest
The authors have no conflict of interest to declare.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Jeantin, L., Shor, N., Coustans, M. et al. Progressive multifocal leukoencephalopathy in patients with chronic liver disease successfully treated with pembrolizumab. J Neurol 271, 2119–2124 (2024). https://doi.org/10.1007/s00415-023-12163-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-023-12163-6